Navidea Biopharmaceuticals Announces the Presentation of Data at Upcoming Scientific Meetings in July
Clinical trial data from oncology and Alzheimer’s disease product candidates to be presented at EACR, International Head and Neck Cancer and Alzheimer's Association International Conferences
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek program were accepted for presentation at the European Association for Cancer Research (EACR) and the American Head and Neck Society’s 8th International Conference on Head and Neck Cancer Conference. In addition, data from its AZD4694 program were accepted for presentation at the Alzheimer's Association International Conference on Alzheimer's Disease (AAIC). Details of the presentations from the Phase 3 clinical studies investigating Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer, breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its Alzheimer’s Disease candidate, AZD4694 are listed below.
European Association for Cancer Research
|Date:||July 7-10, 2012|
Enhanced Sentinel Node Evaluation in Breast Cancer, Melanoma, and Head/Neck Squamous Cell Carcinoma Via CD206 Receptor Targeting With Tc99m-tilmanocept
|Author:||Frederick Cope, PhD, Navidea Biopharmaceuticals|
|Session, Date:||Poster Sessions, July 8-9, 2012|
Alzheimer's Association International Conference on Alzheimer's Disease- AAIC
|Date:||July 14-19, 2012|
|Location:||Vancouver, BC, Canada|
Head to head comparison of 11C-PiB and 18F-AZD4694 for Aβ imaging in ageing and dementia
|Author:||Christopher Rowe, MD FRACP, Austin Health, Melbourne Australia|
|Session, Date:||Neuroimaging 1: Amyloid Imaging Validation and Correlation|
|Sunday, July 15, 2012|
Amyloid PET Imaging Using AZD4694 and Unusually Brief Radiotracer Reuptake and Scanning Periods.
|Author:||Kewei Chen, PhD, Banner Alzheimer’s Institute, Phoenix, AZ|
|Session, Date:||Novel Tracers and Techniques for Imaging in AD (Session Number: 2860)|
|Saturday, July 14, 2012|
Comparison of the fluorinated β-amyloid imaging agents florbetapir, florbetaben and AZD4694
|Author:||Samuel Svensson, AstraZeneca, Södertälje, Sweden|
|Session, Date:||Poster Session, July 14, 2012|
8th International Conference on Head and Neck Cancer (AHNS)
|Date:||July 21-25, 2012|
Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node (SLN) mapping in head and neck squamous cell carcinoma (SCCa): Initial report of institutional experience in an ongoing Phase 3 study (S146)
|Author:||Amit Agrawal, MD, The Ohio State University, Columbus, OH|
|Date:||Monday, July 23, 13:53 PM|
99m-Tc-Tilmanocept-Identified Sentinel Lymph Nodes Relative to the Pathological Status of Non-Sentinel Lymph Nodes in an Elective Neck Dissection in Cutaneous and Intraoral Head and Neck Squamous Cell Carcinoma: A Single Institutional Experience (S150)
Stephen Y. Lai, MD PhD, et al., University of Texas, MD Anderson Cancer Center, Houston, TX
|Date:||Monday, July 23, 14:31 PM|
Clinical Experience at the University of Miami in a Phase 3 Trial Using Receptor Targeted 99mTc-Tilmanocept to Identify and Evaluate the Pathological Status of Sentinel Lymph Nodes (SLNs) vs. Elective Neck Dissection (END) for Patients with Intraoral Squamous Cell Carcinoma
|Author:||Francisco Civantos, MD, University of Miami, Miami, FL|
|Date:||Poster Sessions, July 22-23, 2012|
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released July 6, 2012